Fenghuang Zhan
Concepts (592)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 139 | 2025 | 2999 | 10.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 53 | 2025 | 853 | 3.140 |
Why?
| | Drug Resistance, Neoplasm | 25 | 2020 | 324 | 2.960 |
Why?
| | Plasma Cells | 24 | 2025 | 234 | 2.870 |
Why?
| | Gene Expression Profiling | 44 | 2025 | 1101 | 2.740 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 9 | 2025 | 120 | 2.630 |
Why?
| | Cell Proliferation | 25 | 2022 | 1017 | 2.080 |
Why?
| | Antineoplastic Agents | 29 | 2020 | 1214 | 1.990 |
Why?
| | Cell Line, Tumor | 46 | 2025 | 1418 | 1.870 |
Why?
| | Neoplastic Stem Cells | 7 | 2020 | 90 | 1.590 |
Why?
| | Pyrazines | 19 | 2023 | 188 | 1.480 |
Why?
| | Disease Progression | 19 | 2025 | 866 | 1.480 |
Why?
| | Mice | 48 | 2025 | 5877 | 1.380 |
Why?
| | Humans | 161 | 2025 | 52114 | 1.370 |
Why?
| | Paraproteinemias | 9 | 2024 | 72 | 1.360 |
Why?
| | Lymphoma, B-Cell | 5 | 2021 | 61 | 1.330 |
Why?
| | Apoptosis | 18 | 2025 | 1117 | 1.330 |
Why?
| | Prognosis | 39 | 2025 | 2093 | 1.300 |
Why?
| | Bone Resorption | 6 | 2024 | 302 | 1.290 |
Why?
| | Boronic Acids | 17 | 2014 | 181 | 1.290 |
Why?
| | Animals | 59 | 2025 | 13332 | 1.200 |
Why?
| | Tumor Microenvironment | 6 | 2024 | 246 | 1.170 |
Why?
| | Neoplasm Proteins | 7 | 2021 | 328 | 1.120 |
Why?
| | Osteolysis | 4 | 2022 | 74 | 1.050 |
Why?
| | B-Lymphocytes | 8 | 2021 | 180 | 1.010 |
Why?
| | Cell Cycle Proteins | 4 | 2023 | 167 | 0.970 |
Why?
| | T-Lymphocytes | 8 | 2024 | 316 | 0.950 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2024 | 597 | 0.920 |
Why?
| | Ubiquitination | 3 | 2021 | 57 | 0.880 |
Why?
| | Proteasome Inhibitors | 7 | 2020 | 101 | 0.870 |
Why?
| | Signal Transduction | 21 | 2023 | 1699 | 0.820 |
Why?
| | Proteasome Endopeptidase Complex | 4 | 2018 | 138 | 0.770 |
Why?
| | MicroRNAs | 7 | 2022 | 385 | 0.770 |
Why?
| | Antigens, CD | 8 | 2024 | 215 | 0.720 |
Why?
| | Neoplasms | 3 | 2024 | 1288 | 0.700 |
Why?
| | Iron | 3 | 2017 | 130 | 0.670 |
Why?
| | Ascorbic Acid | 2 | 2017 | 25 | 0.660 |
Why?
| | Carrier Proteins | 3 | 2017 | 316 | 0.620 |
Why?
| | CDC2-CDC28 Kinases | 3 | 2015 | 11 | 0.620 |
Why?
| | Cation Transport Proteins | 2 | 2019 | 26 | 0.610 |
Why?
| | Chromosome Aberrations | 7 | 2025 | 295 | 0.610 |
Why?
| | Ubiquitins | 2 | 2016 | 18 | 0.590 |
Why?
| | Up-Regulation | 6 | 2020 | 459 | 0.590 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2010 | 26 | 0.590 |
Why?
| | Mice, Inbred NOD | 5 | 2020 | 90 | 0.580 |
Why?
| | Oligonucleotide Array Sequence Analysis | 19 | 2014 | 411 | 0.580 |
Why?
| | Glycolysis | 3 | 2022 | 72 | 0.580 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2018 | 38 | 0.580 |
Why?
| | Cell Survival | 11 | 2020 | 596 | 0.560 |
Why?
| | Cell Differentiation | 9 | 2023 | 670 | 0.550 |
Why?
| | Proto-Oncogene Proteins c-akt | 5 | 2023 | 170 | 0.550 |
Why?
| | Pyrimidines | 3 | 2015 | 198 | 0.540 |
Why?
| | STAT3 Transcription Factor | 4 | 2016 | 86 | 0.540 |
Why?
| | Killer Cells, Natural | 5 | 2024 | 112 | 0.530 |
Why?
| | Pyruvate Kinase | 1 | 2017 | 7 | 0.530 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1020 | 0.520 |
Why?
| | RNA Splicing | 1 | 2017 | 41 | 0.510 |
Why?
| | Female | 46 | 2025 | 28055 | 0.490 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2015 | 87 | 0.480 |
Why?
| | Down-Regulation | 9 | 2019 | 343 | 0.480 |
Why?
| | Male | 36 | 2025 | 26652 | 0.480 |
Why?
| | Cyclopentanes | 1 | 2015 | 12 | 0.470 |
Why?
| | Transplantation, Autologous | 5 | 2024 | 480 | 0.470 |
Why?
| | Thalidomide | 10 | 2023 | 377 | 0.470 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 68 | 0.460 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2014 | 24 | 0.450 |
Why?
| | Osteoclasts | 7 | 2023 | 427 | 0.450 |
Why?
| | Dexamethasone | 7 | 2024 | 435 | 0.440 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2020 | 17 | 0.430 |
Why?
| | Flow Cytometry | 8 | 2018 | 397 | 0.420 |
Why?
| | Hematologic Neoplasms | 1 | 2015 | 100 | 0.420 |
Why?
| | Models, Biological | 5 | 2018 | 731 | 0.410 |
Why?
| | Receptors, Retinoic Acid | 2 | 2013 | 22 | 0.410 |
Why?
| | Cystatin M | 2 | 2024 | 17 | 0.410 |
Why?
| | RNA, Messenger | 13 | 2021 | 1135 | 0.400 |
Why?
| | B-Cell Maturation Antigen | 2 | 2024 | 92 | 0.390 |
Why?
| | Antigens, Neoplasm | 6 | 2014 | 146 | 0.390 |
Why?
| | Aged | 26 | 2025 | 10142 | 0.380 |
Why?
| | Mice, Transgenic | 7 | 2021 | 560 | 0.380 |
Why?
| | Glucuronidase | 4 | 2018 | 47 | 0.380 |
Why?
| | Predictive Value of Tests | 5 | 2016 | 939 | 0.360 |
Why?
| | Antibodies, Bispecific | 2 | 2023 | 88 | 0.350 |
Why?
| | Syndecan-1 | 6 | 2017 | 73 | 0.350 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 6 | 0.340 |
Why?
| | Arsenicals | 1 | 2010 | 15 | 0.340 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 20 | 0.340 |
Why?
| | Oxides | 1 | 2010 | 21 | 0.340 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 12 | 2015 | 580 | 0.330 |
Why?
| | Janus Kinase 1 | 1 | 2010 | 16 | 0.330 |
Why?
| | Proto-Oncogene Proteins c-jun | 2 | 2009 | 76 | 0.330 |
Why?
| | Middle Aged | 25 | 2025 | 13028 | 0.330 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2010 | 23 | 0.330 |
Why?
| | Immunotherapy, Adoptive | 2 | 2024 | 155 | 0.330 |
Why?
| | DNA-Binding Proteins | 4 | 2021 | 424 | 0.320 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 83 | 0.320 |
Why?
| | Early Growth Response Protein 1 | 1 | 2009 | 34 | 0.310 |
Why?
| | Transcription Factors | 6 | 2022 | 564 | 0.310 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 105 | 0.310 |
Why?
| | Oligopeptides | 3 | 2015 | 92 | 0.300 |
Why?
| | Tretinoin | 1 | 2009 | 53 | 0.300 |
Why?
| | Membrane Proteins | 4 | 2018 | 328 | 0.300 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2019 | 216 | 0.300 |
Why?
| | Osteogenesis | 5 | 2023 | 365 | 0.290 |
Why?
| | NF-kappa B | 3 | 2018 | 329 | 0.290 |
Why?
| | Tumor Cells, Cultured | 6 | 2020 | 445 | 0.280 |
Why?
| | Genes, Neoplasm | 1 | 2008 | 31 | 0.280 |
Why?
| | Antibodies | 3 | 2024 | 148 | 0.280 |
Why?
| | Microarray Analysis | 3 | 2018 | 69 | 0.280 |
Why?
| | Adult | 22 | 2025 | 14095 | 0.270 |
Why?
| | Chromosomes, Human, Pair 1 | 4 | 2023 | 95 | 0.270 |
Why?
| | Oxidative Stress | 5 | 2017 | 809 | 0.270 |
Why?
| | Immunologic Factors | 5 | 2015 | 117 | 0.270 |
Why?
| | Interleukin-6 | 3 | 2019 | 274 | 0.270 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2007 | 2 | 0.270 |
Why?
| | Retrospective Studies | 8 | 2025 | 6610 | 0.260 |
Why?
| | Neoplasms, Plasma Cell | 2 | 2023 | 35 | 0.260 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2008 | 224 | 0.260 |
Why?
| | Small Molecule Libraries | 2 | 2019 | 66 | 0.260 |
Why?
| | Aged, 80 and over | 8 | 2025 | 3382 | 0.260 |
Why?
| | Pyrazoles | 2 | 2020 | 113 | 0.260 |
Why?
| | Mice, SCID | 9 | 2018 | 178 | 0.240 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2024 | 128 | 0.240 |
Why?
| | Endopeptidase Clp | 1 | 2025 | 2 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 3 | 2024 | 225 | 0.240 |
Why?
| | Risk Factors | 11 | 2018 | 3922 | 0.230 |
Why?
| | Genomics | 2 | 2023 | 265 | 0.230 |
Why?
| | Survival Rate | 8 | 2020 | 945 | 0.230 |
Why?
| | Enzyme Inhibitors | 4 | 2019 | 371 | 0.230 |
Why?
| | Bone Diseases | 4 | 2016 | 92 | 0.230 |
Why?
| | Bone Marrow | 7 | 2024 | 361 | 0.220 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2021 | 48 | 0.220 |
Why?
| | ROC Curve | 1 | 2025 | 250 | 0.220 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2025 | 132 | 0.220 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 71 | 0.220 |
Why?
| | Transcriptome | 2 | 2025 | 363 | 0.210 |
Why?
| | Propionates | 1 | 2024 | 23 | 0.210 |
Why?
| | Receptors, LDL | 1 | 2024 | 73 | 0.210 |
Why?
| | Hydroxybenzoates | 1 | 2024 | 24 | 0.210 |
Why?
| | TNF Receptor-Associated Factor 3 | 2 | 2022 | 13 | 0.210 |
Why?
| | Ferritins | 1 | 2024 | 36 | 0.210 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 15 | 0.210 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 77 | 0.210 |
Why?
| | Melphalan | 3 | 2023 | 178 | 0.210 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 75 | 0.210 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2015 | 47 | 0.210 |
Why?
| | Bone Marrow Cells | 4 | 2015 | 189 | 0.210 |
Why?
| | Antigens, CD19 | 3 | 2018 | 28 | 0.210 |
Why?
| | Cholesterol | 1 | 2024 | 160 | 0.210 |
Why?
| | Proteolysis | 4 | 2018 | 102 | 0.210 |
Why?
| | Positron-Emission Tomography | 1 | 2025 | 297 | 0.210 |
Why?
| | Membrane Glycoproteins | 6 | 2009 | 238 | 0.200 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2024 | 184 | 0.200 |
Why?
| | Genes, myc | 3 | 2019 | 39 | 0.200 |
Why?
| | Intercellular Signaling Peptides and Proteins | 4 | 2007 | 106 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-myc | 3 | 2025 | 53 | 0.200 |
Why?
| | Lymphoma | 1 | 2024 | 71 | 0.200 |
Why?
| | Bone Diseases, Metabolic | 1 | 2024 | 78 | 0.200 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 162 | 0.200 |
Why?
| | Homeostasis | 1 | 2024 | 205 | 0.200 |
Why?
| | Cluster Analysis | 5 | 2009 | 236 | 0.200 |
Why?
| | Gene Knockdown Techniques | 3 | 2018 | 108 | 0.200 |
Why?
| | Bone and Bones | 2 | 2021 | 492 | 0.200 |
Why?
| | Phenols | 1 | 2024 | 92 | 0.200 |
Why?
| | Neutropenia | 1 | 2023 | 113 | 0.190 |
Why?
| | NM23 Nucleoside Diphosphate Kinases | 1 | 2022 | 4 | 0.190 |
Why?
| | Protein Binding | 2 | 2018 | 665 | 0.190 |
Why?
| | Recurrence | 7 | 2018 | 680 | 0.190 |
Why?
| | Periodontitis | 1 | 2022 | 11 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2016 | 608 | 0.190 |
Why?
| | Antibodies, Monoclonal | 3 | 2013 | 475 | 0.190 |
Why?
| | Case-Control Studies | 8 | 2020 | 1193 | 0.190 |
Why?
| | In Situ Hybridization, Fluorescence | 5 | 2023 | 262 | 0.190 |
Why?
| | Reactive Oxygen Species | 4 | 2017 | 421 | 0.190 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 166 | 0.180 |
Why?
| | Osteoporosis | 1 | 2023 | 160 | 0.180 |
Why?
| | Protein Stability | 2 | 2020 | 45 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 5 | 2016 | 482 | 0.180 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 116 | 0.180 |
Why?
| | Mitochondria | 1 | 2025 | 421 | 0.180 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 1 | 0.180 |
Why?
| | Nuclear Factor 90 Proteins | 1 | 2021 | 1 | 0.180 |
Why?
| | RANK Ligand | 1 | 2022 | 187 | 0.170 |
Why?
| | Venous Thromboembolism | 3 | 2011 | 75 | 0.170 |
Why?
| | Gene Expression Regulation | 3 | 2022 | 1000 | 0.170 |
Why?
| | Gene Expression | 4 | 2017 | 618 | 0.170 |
Why?
| | Phenylpropionates | 1 | 2021 | 13 | 0.170 |
Why?
| | Hippurates | 1 | 2021 | 10 | 0.170 |
Why?
| | Cell Cycle | 4 | 2010 | 237 | 0.170 |
Why?
| | Bone Neoplasms | 2 | 2015 | 184 | 0.170 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 198 | 0.170 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2020 | 136 | 0.170 |
Why?
| | Treatment Outcome | 12 | 2020 | 5456 | 0.170 |
Why?
| | Protease Inhibitors | 3 | 2011 | 59 | 0.170 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 54 | 0.170 |
Why?
| | Antigens, CD20 | 2 | 2014 | 6 | 0.170 |
Why?
| | Neoplasm Metastasis | 4 | 2015 | 236 | 0.170 |
Why?
| | Cell Movement | 2 | 2015 | 273 | 0.170 |
Why?
| | Time Factors | 8 | 2021 | 2970 | 0.170 |
Why?
| | Evolution, Molecular | 1 | 2021 | 95 | 0.160 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 59 | 0.160 |
Why?
| | Disease-Free Survival | 7 | 2016 | 462 | 0.160 |
Why?
| | Colorectal Neoplasms | 2 | 2022 | 292 | 0.160 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 494 | 0.160 |
Why?
| | Chromosomal Instability | 3 | 2021 | 16 | 0.160 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2015 | 56 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 463 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 630 | 0.160 |
Why?
| | Tumor Suppressor Proteins | 2 | 2019 | 128 | 0.160 |
Why?
| | DNA, Single-Stranded | 1 | 2020 | 88 | 0.150 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2019 | 47 | 0.150 |
Why?
| | Oncogene Proteins | 1 | 2019 | 19 | 0.150 |
Why?
| | Mitosis | 3 | 2015 | 87 | 0.150 |
Why?
| | rab GTP-Binding Proteins | 1 | 2019 | 23 | 0.150 |
Why?
| | Excitation Contraction Coupling | 1 | 2018 | 3 | 0.150 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2019 | 25 | 0.150 |
Why?
| | Transplantation, Heterologous | 2 | 2017 | 78 | 0.150 |
Why?
| | Receptors, Interleukin-6 | 1 | 2018 | 23 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2022 | 296 | 0.150 |
Why?
| | Neovascularization, Pathologic | 3 | 2009 | 158 | 0.150 |
Why?
| | Drug Tolerance | 1 | 2018 | 60 | 0.150 |
Why?
| | Adaptation, Physiological | 2 | 2018 | 110 | 0.150 |
Why?
| | Pyridines | 1 | 2019 | 134 | 0.140 |
Why?
| | Blotting, Western | 3 | 2015 | 588 | 0.140 |
Why?
| | Myocardial Contraction | 1 | 2018 | 112 | 0.140 |
Why?
| | Cardiomegaly | 1 | 2018 | 57 | 0.140 |
Why?
| | Ventricular Remodeling | 1 | 2018 | 65 | 0.140 |
Why?
| | Cell Nucleus | 1 | 2018 | 188 | 0.140 |
Why?
| | Lung Neoplasms | 1 | 2024 | 624 | 0.140 |
Why?
| | Glucaric Acid | 1 | 2017 | 2 | 0.140 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 399 | 0.140 |
Why?
| | Ferric Compounds | 1 | 2017 | 16 | 0.140 |
Why?
| | beta Catenin | 2 | 2015 | 103 | 0.130 |
Why?
| | Mice, Knockout | 4 | 2023 | 893 | 0.130 |
Why?
| | Myocytes, Cardiac | 1 | 2018 | 145 | 0.130 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2017 | 5 | 0.130 |
Why?
| | Hydroxamic Acids | 2 | 2014 | 38 | 0.130 |
Why?
| | Aerobiosis | 1 | 2017 | 13 | 0.130 |
Why?
| | Microfilament Proteins | 1 | 2017 | 44 | 0.130 |
Why?
| | Onium Compounds | 1 | 2016 | 13 | 0.130 |
Why?
| | Calcium-Binding Proteins | 1 | 2017 | 57 | 0.130 |
Why?
| | Thyroid Hormones | 1 | 2017 | 22 | 0.130 |
Why?
| | Organophosphorus Compounds | 1 | 2016 | 17 | 0.130 |
Why?
| | Deoxyglucose | 1 | 2016 | 35 | 0.130 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2014 | 57 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2019 | 202 | 0.130 |
Why?
| | Survival Analysis | 6 | 2020 | 667 | 0.130 |
Why?
| | Inhibitor of Apoptosis Proteins | 3 | 2015 | 21 | 0.130 |
Why?
| | Gene Deletion | 2 | 2008 | 274 | 0.130 |
Why?
| | Syndecans | 3 | 2006 | 37 | 0.120 |
Why?
| | RNA Interference | 2 | 2015 | 185 | 0.120 |
Why?
| | Cell Death | 1 | 2016 | 169 | 0.120 |
Why?
| | Ribosomal Proteins | 1 | 2016 | 24 | 0.120 |
Why?
| | Macrophages | 2 | 2022 | 360 | 0.120 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 45 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 2 | 2009 | 149 | 0.120 |
Why?
| | Neoplasm Staging | 4 | 2025 | 766 | 0.120 |
Why?
| | Proteoglycans | 3 | 2006 | 86 | 0.120 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 21 | 0.120 |
Why?
| | Muscle Proteins | 1 | 2018 | 348 | 0.120 |
Why?
| | Gene Dosage | 2 | 2013 | 76 | 0.120 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 88 | 0.120 |
Why?
| | Calcium Channels | 1 | 2015 | 39 | 0.120 |
Why?
| | Polysaccharides | 1 | 2015 | 54 | 0.120 |
Why?
| | Receptors, Transferrin | 1 | 2015 | 16 | 0.120 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 46 | 0.120 |
Why?
| | Mitochondria, Heart | 1 | 2015 | 40 | 0.120 |
Why?
| | Side-Population Cells | 1 | 2015 | 3 | 0.110 |
Why?
| | Patient Selection | 2 | 2023 | 265 | 0.110 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 110 | 0.110 |
Why?
| | Serine Endopeptidases | 2 | 2006 | 50 | 0.110 |
Why?
| | Lentivirus | 1 | 2015 | 17 | 0.110 |
Why?
| | Retinal Dehydrogenase | 1 | 2014 | 10 | 0.110 |
Why?
| | Transcription, Genetic | 3 | 2018 | 373 | 0.110 |
Why?
| | Adenine | 1 | 2015 | 30 | 0.110 |
Why?
| | Caspase 3 | 2 | 2022 | 91 | 0.110 |
Why?
| | Serum | 1 | 2014 | 32 | 0.110 |
Why?
| | Cell Lineage | 1 | 2014 | 87 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2014 | 33 | 0.110 |
Why?
| | Translocation, Genetic | 4 | 2021 | 265 | 0.110 |
Why?
| | Superoxide Dismutase | 1 | 2014 | 120 | 0.110 |
Why?
| | Tumor Burden | 3 | 2020 | 133 | 0.110 |
Why?
| | Piperidines | 1 | 2015 | 96 | 0.110 |
Why?
| | Stress, Physiological | 1 | 2015 | 184 | 0.110 |
Why?
| | Cyclins | 3 | 2015 | 38 | 0.110 |
Why?
| | HLA Antigens | 1 | 2014 | 53 | 0.110 |
Why?
| | Alkaline Phosphatase | 2 | 2011 | 92 | 0.110 |
Why?
| | Glycoproteins | 1 | 2014 | 122 | 0.110 |
Why?
| | Repressor Proteins | 4 | 2015 | 150 | 0.110 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2013 | 12 | 0.100 |
Why?
| | Leukemia, Plasma Cell | 1 | 2013 | 33 | 0.100 |
Why?
| | Lactate Dehydrogenases | 1 | 2013 | 1 | 0.100 |
Why?
| | Phenotype | 4 | 2009 | 794 | 0.100 |
Why?
| | Genome, Human | 2 | 2021 | 121 | 0.100 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2013 | 59 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2024 | 2282 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 1368 | 0.100 |
Why?
| | Scavenger Receptors, Class A | 1 | 2013 | 39 | 0.100 |
Why?
| | Disease Models, Animal | 4 | 2020 | 1467 | 0.100 |
Why?
| | Leukemia | 1 | 2013 | 67 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2013 | 54 | 0.100 |
Why?
| | Heart | 1 | 2015 | 360 | 0.100 |
Why?
| | Heat-Shock Proteins | 1 | 2013 | 104 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 215 | 0.090 |
Why?
| | RNA, Neoplasm | 3 | 2007 | 45 | 0.090 |
Why?
| | Forkhead Transcription Factors | 2 | 2023 | 119 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2012 | 48 | 0.090 |
Why?
| | Drug Screening Assays, Antitumor | 3 | 2020 | 136 | 0.090 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2011 | 21 | 0.090 |
Why?
| | Activated Protein C Resistance | 1 | 2011 | 10 | 0.090 |
Why?
| | Factor V | 1 | 2011 | 10 | 0.090 |
Why?
| | Protein Isoforms | 2 | 2009 | 124 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2011 | 103 | 0.090 |
Why?
| | Glucocorticoids | 1 | 2013 | 236 | 0.090 |
Why?
| | Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.090 |
Why?
| | Cell Growth Processes | 1 | 2010 | 24 | 0.090 |
Why?
| | HLA-A Antigens | 2 | 2007 | 11 | 0.080 |
Why?
| | Cells, Cultured | 6 | 2015 | 1568 | 0.080 |
Why?
| | Gene Silencing | 2 | 2007 | 120 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 1872 | 0.080 |
Why?
| | Alleles | 2 | 2021 | 277 | 0.080 |
Why?
| | Thrombosis | 1 | 2012 | 252 | 0.080 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 401 | 0.080 |
Why?
| | K562 Cells | 3 | 2016 | 41 | 0.080 |
Why?
| | Immunophenotyping | 5 | 2010 | 117 | 0.080 |
Why?
| | Microtubule-Associated Proteins | 1 | 2009 | 61 | 0.080 |
Why?
| | Recombinant Proteins | 1 | 2010 | 492 | 0.080 |
Why?
| | Bone Remodeling | 1 | 2010 | 154 | 0.080 |
Why?
| | Chromosome Mapping | 2 | 2006 | 149 | 0.080 |
Why?
| | HCT116 Cells | 2 | 2020 | 31 | 0.080 |
Why?
| | Thromboembolism | 1 | 2009 | 49 | 0.080 |
Why?
| | Mutation | 3 | 2021 | 1318 | 0.070 |
Why?
| | Lymphocyte Subsets | 1 | 2008 | 14 | 0.070 |
Why?
| | ras Proteins | 2 | 2020 | 63 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 184 | 0.070 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 36 | 0.070 |
Why?
| | Neoplasm Transplantation | 2 | 2020 | 86 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2007 | 1199 | 0.070 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 2 | 2020 | 9 | 0.070 |
Why?
| | Risk Assessment | 3 | 2025 | 1339 | 0.070 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2007 | 14 | 0.070 |
Why?
| | Adoptive Transfer | 1 | 2007 | 29 | 0.070 |
Why?
| | Genes, abl | 1 | 2007 | 2 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 1665 | 0.070 |
Why?
| | HEK293 Cells | 2 | 2019 | 231 | 0.070 |
Why?
| | Cancer Vaccines | 1 | 2007 | 78 | 0.060 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 72 | 0.060 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2021 | 141 | 0.060 |
Why?
| | Caspases | 1 | 2007 | 102 | 0.060 |
Why?
| | Cyclin D | 1 | 2006 | 18 | 0.060 |
Why?
| | Chromosome Banding | 1 | 2006 | 24 | 0.060 |
Why?
| | Models, Genetic | 1 | 2006 | 173 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 439 | 0.060 |
Why?
| | Palatine Tonsil | 2 | 2003 | 11 | 0.060 |
Why?
| | DNA Damage | 1 | 2008 | 306 | 0.060 |
Why?
| | Peptides | 1 | 2007 | 234 | 0.060 |
Why?
| | Maf Transcription Factors, Large | 1 | 2005 | 1 | 0.060 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 181 | 0.060 |
Why?
| | Doxorubicin | 2 | 2018 | 242 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 168 | 0.060 |
Why?
| | Protein Kinases | 1 | 2005 | 72 | 0.060 |
Why?
| | Cyclin D1 | 1 | 2005 | 57 | 0.060 |
Why?
| | Antibody Formation | 1 | 2005 | 51 | 0.060 |
Why?
| | Hydrogen Peroxide | 2 | 2017 | 119 | 0.060 |
Why?
| | Protein Biosynthesis | 2 | 2003 | 265 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2025 | 170 | 0.050 |
Why?
| | Base Sequence | 3 | 2015 | 627 | 0.050 |
Why?
| | Papillomaviridae | 1 | 2005 | 104 | 0.050 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2004 | 73 | 0.050 |
Why?
| | Carcinoma, Papillary | 1 | 2004 | 50 | 0.050 |
Why?
| | Transfection | 2 | 2020 | 366 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2019 | 307 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 190 | 0.050 |
Why?
| | Drug Synergism | 2 | 2014 | 148 | 0.050 |
Why?
| | Jurkat Cells | 2 | 2014 | 28 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 528 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2004 | 69 | 0.050 |
Why?
| | Zebrafish Proteins | 1 | 2003 | 24 | 0.050 |
Why?
| | Adipogenesis | 1 | 2024 | 49 | 0.050 |
Why?
| | Glucose | 2 | 2016 | 358 | 0.050 |
Why?
| | Ovariectomy | 1 | 2024 | 113 | 0.050 |
Why?
| | Steroids | 1 | 2024 | 60 | 0.050 |
Why?
| | PPAR gamma | 1 | 2024 | 72 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2024 | 96 | 0.050 |
Why?
| | Integrin beta Chains | 1 | 2023 | 14 | 0.050 |
Why?
| | Integrins | 1 | 2023 | 31 | 0.050 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2003 | 38 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2023 | 45 | 0.050 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.050 |
Why?
| | Cytogenetic Analysis | 1 | 2023 | 79 | 0.050 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2002 | 30 | 0.050 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2002 | 75 | 0.050 |
Why?
| | Macrophage Activation | 1 | 2022 | 22 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2023 | 139 | 0.050 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2002 | 60 | 0.050 |
Why?
| | Computational Biology | 2 | 2020 | 209 | 0.050 |
Why?
| | Geography | 1 | 2022 | 65 | 0.050 |
Why?
| | Porphyromonas gingivalis | 1 | 2022 | 17 | 0.050 |
Why?
| | Chromatin | 1 | 2023 | 141 | 0.050 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2005 | 299 | 0.050 |
Why?
| | Diploidy | 3 | 2007 | 25 | 0.050 |
Why?
| | Inflammasomes | 1 | 2022 | 66 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2002 | 146 | 0.040 |
Why?
| | Models, Animal | 2 | 2015 | 228 | 0.040 |
Why?
| | Mutation Rate | 1 | 2021 | 36 | 0.040 |
Why?
| | DNA Primers | 2 | 2015 | 204 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 76 | 0.040 |
Why?
| | Proteins | 1 | 2003 | 347 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 68 | 0.040 |
Why?
| | Genes, Tumor Suppressor | 1 | 2021 | 73 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2004 | 458 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 117 | 0.040 |
Why?
| | Cytokines | 3 | 2009 | 621 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2014 | 718 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 95 | 0.040 |
Why?
| | 3' Untranslated Regions | 1 | 2020 | 55 | 0.040 |
Why?
| | Immunohistochemistry | 3 | 2009 | 975 | 0.040 |
Why?
| | Software | 1 | 2002 | 280 | 0.040 |
Why?
| | DNA | 1 | 2023 | 543 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2019 | 46 | 0.040 |
Why?
| | Genetic Variation | 1 | 2020 | 224 | 0.040 |
Why?
| | Drug Discovery | 1 | 2020 | 93 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2019 | 156 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 231 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 174 | 0.040 |
Why?
| | Protein Phosphatase 2 | 1 | 2019 | 4 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 600 | 0.040 |
Why?
| | G1 Phase | 1 | 2019 | 13 | 0.040 |
Why?
| | Enzyme Activators | 1 | 2019 | 8 | 0.040 |
Why?
| | Immunotherapy | 1 | 2021 | 240 | 0.040 |
Why?
| | Protein Conformation | 1 | 2019 | 177 | 0.040 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 12 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2020 | 404 | 0.040 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2018 | 35 | 0.040 |
Why?
| | Wnt Proteins | 2 | 2013 | 102 | 0.040 |
Why?
| | Calpain | 1 | 2018 | 25 | 0.040 |
Why?
| | DNA Methylation | 1 | 2023 | 583 | 0.040 |
Why?
| | Phosphorylation | 1 | 2020 | 523 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 82 | 0.040 |
Why?
| | Drug Resistance | 1 | 2018 | 68 | 0.040 |
Why?
| | Autophagy | 1 | 2020 | 195 | 0.040 |
Why?
| | Deferoxamine | 1 | 2017 | 9 | 0.030 |
Why?
| | HT29 Cells | 1 | 2017 | 14 | 0.030 |
Why?
| | Iron Chelating Agents | 1 | 2017 | 12 | 0.030 |
Why?
| | Catalase | 1 | 2017 | 72 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2017 | 32 | 0.030 |
Why?
| | Biological Transport | 1 | 2016 | 150 | 0.030 |
Why?
| | Chronic Disease | 1 | 2019 | 585 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2016 | 83 | 0.030 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2016 | 49 | 0.030 |
Why?
| | Models, Statistical | 2 | 2008 | 231 | 0.030 |
Why?
| | Drug Interactions | 1 | 2016 | 201 | 0.030 |
Why?
| | Cell Line | 2 | 2013 | 1018 | 0.030 |
Why?
| | Mice, Inbred ICR | 1 | 2016 | 25 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2015 | 69 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 128 | 0.030 |
Why?
| | Pharmacogenetics | 2 | 2006 | 51 | 0.030 |
Why?
| | Reoviridae | 1 | 2015 | 25 | 0.030 |
Why?
| | Vidarabine | 1 | 2015 | 8 | 0.030 |
Why?
| | Mitoxantrone | 1 | 2015 | 9 | 0.030 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2015 | 21 | 0.030 |
Why?
| | Genes, Dominant | 1 | 2015 | 21 | 0.030 |
Why?
| | Myocardial Reperfusion | 1 | 2015 | 13 | 0.030 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2015 | 25 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 47 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 68 | 0.030 |
Why?
| | Vincristine | 1 | 2015 | 88 | 0.030 |
Why?
| | Cytosol | 1 | 2015 | 80 | 0.030 |
Why?
| | China | 1 | 2015 | 134 | 0.030 |
Why?
| | Prednisone | 1 | 2015 | 102 | 0.030 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2015 | 34 | 0.030 |
Why?
| | Ligands | 1 | 2015 | 206 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2015 | 140 | 0.030 |
Why?
| | Vaccination | 2 | 2007 | 296 | 0.030 |
Why?
| | Glutathione Peroxidase | 1 | 2014 | 23 | 0.030 |
Why?
| | Cyclin B | 1 | 2014 | 4 | 0.030 |
Why?
| | CDC2 Protein Kinase | 1 | 2014 | 15 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 132 | 0.030 |
Why?
| | Disulfiram | 1 | 2014 | 13 | 0.030 |
Why?
| | Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2015 | 173 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2015 | 200 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 41 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 121 | 0.030 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2013 | 8 | 0.030 |
Why?
| | Lectins, C-Type | 1 | 2013 | 30 | 0.030 |
Why?
| | Veratrum Alkaloids | 1 | 2013 | 5 | 0.030 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2013 | 17 | 0.030 |
Why?
| | Calcium | 1 | 2015 | 372 | 0.030 |
Why?
| | Isoxazoles | 1 | 2013 | 15 | 0.030 |
Why?
| | Glutathione | 1 | 2014 | 303 | 0.030 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 17 | 0.030 |
Why?
| | Sulfones | 1 | 2013 | 24 | 0.030 |
Why?
| | Electrocardiography | 1 | 2015 | 279 | 0.030 |
Why?
| | Hedgehog Proteins | 1 | 2013 | 34 | 0.030 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2013 | 32 | 0.030 |
Why?
| | Itraconazole | 1 | 2013 | 38 | 0.030 |
Why?
| | Peptide Library | 1 | 2013 | 16 | 0.030 |
Why?
| | Receptors, Glucocorticoid | 1 | 2013 | 34 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2013 | 24 | 0.020 |
Why?
| | Oxidants | 1 | 2013 | 51 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2015 | 264 | 0.020 |
Why?
| | Azacitidine | 1 | 2013 | 39 | 0.020 |
Why?
| | ADP-ribosyl Cyclase | 2 | 2003 | 4 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 94 | 0.020 |
Why?
| | Epitopes | 1 | 2013 | 62 | 0.020 |
Why?
| | Hydrocortisone | 1 | 2013 | 113 | 0.020 |
Why?
| | Prospective Studies | 2 | 2010 | 2424 | 0.020 |
Why?
| | Blood Pressure | 1 | 2015 | 535 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2013 | 126 | 0.020 |
Why?
| | Histone Deacetylases | 1 | 2013 | 51 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 128 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2013 | 101 | 0.020 |
Why?
| | Myocardium | 1 | 2015 | 477 | 0.020 |
Why?
| | Osteoblasts | 2 | 2006 | 473 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2012 | 47 | 0.020 |
Why?
| | Viper Venoms | 1 | 2011 | 6 | 0.020 |
Why?
| | Protein C | 1 | 2011 | 20 | 0.020 |
Why?
| | Risk | 1 | 2011 | 312 | 0.020 |
Why?
| | Bone Density Conservation Agents | 1 | 2010 | 75 | 0.020 |
Why?
| | Diphosphonates | 1 | 2010 | 92 | 0.020 |
Why?
| | Databases as Topic | 1 | 2009 | 38 | 0.020 |
Why?
| | Parathyroid Hormone | 1 | 2010 | 149 | 0.020 |
Why?
| | Lymphocytes | 1 | 2010 | 146 | 0.020 |
Why?
| | Cytoskeleton | 1 | 2008 | 39 | 0.020 |
Why?
| | Genotype | 1 | 2009 | 563 | 0.020 |
Why?
| | Twins | 1 | 2007 | 33 | 0.020 |
Why?
| | STAT Transcription Factors | 1 | 2007 | 8 | 0.020 |
Why?
| | Cytological Techniques | 1 | 2007 | 13 | 0.020 |
Why?
| | NF-kappa B p52 Subunit | 1 | 2007 | 6 | 0.020 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 17 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2009 | 232 | 0.020 |
Why?
| | I-kappa B Kinase | 1 | 2007 | 20 | 0.020 |
Why?
| | Karyotyping | 1 | 2007 | 78 | 0.020 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 65 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2007 | 11 | 0.020 |
Why?
| | Benzamides | 1 | 2007 | 50 | 0.020 |
Why?
| | Antigen Presentation | 1 | 2007 | 26 | 0.020 |
Why?
| | Remission Induction | 1 | 2007 | 218 | 0.020 |
Why?
| | Polysaccharide-Lyases | 1 | 2007 | 7 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2007 | 122 | 0.020 |
Why?
| | Plasmids | 1 | 2007 | 164 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 234 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2007 | 172 | 0.020 |
Why?
| | Tissue Culture Techniques | 1 | 2007 | 42 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2007 | 269 | 0.020 |
Why?
| | Multigene Family | 1 | 2006 | 49 | 0.020 |
Why?
| | Piperazines | 1 | 2007 | 125 | 0.020 |
Why?
| | Anticoagulants | 1 | 2009 | 276 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 112 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1031 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2006 | 53 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2007 | 133 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 460 | 0.020 |
Why?
| | Incidence | 1 | 2009 | 1070 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 2007 | 131 | 0.020 |
Why?
| | Gelatinases | 1 | 2006 | 32 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2006 | 41 | 0.020 |
Why?
| | Endopeptidases | 1 | 2006 | 63 | 0.020 |
Why?
| | Rabbits | 1 | 2006 | 371 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2006 | 142 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2007 | 634 | 0.010 |
Why?
| | Cyclin D3 | 1 | 2005 | 5 | 0.010 |
Why?
| | Cyclin D2 | 1 | 2005 | 21 | 0.010 |
Why?
| | Adipocytes | 1 | 2006 | 130 | 0.010 |
Why?
| | Trisomy | 1 | 2005 | 35 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2004 | 19 | 0.010 |
Why?
| | Stem Cells | 1 | 2006 | 182 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 766 | 0.010 |
Why?
| | Epithelium | 1 | 2004 | 64 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2006 | 257 | 0.010 |
Why?
| | Ovary | 1 | 2004 | 103 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2006 | 281 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2007 | 337 | 0.010 |
Why?
| | Databases, Factual | 1 | 2007 | 714 | 0.010 |
Why?
| | RNA, Complementary | 1 | 2003 | 2 | 0.010 |
Why?
| | Autocrine Communication | 1 | 2003 | 7 | 0.010 |
Why?
| | Paracrine Communication | 1 | 2003 | 13 | 0.010 |
Why?
| | Cell Separation | 1 | 2003 | 73 | 0.010 |
Why?
| | Metaphase | 1 | 2003 | 46 | 0.010 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2002 | 18 | 0.010 |
Why?
| | Biopsy | 1 | 2005 | 599 | 0.010 |
Why?
| | NAD+ Nucleosidase | 1 | 2002 | 2 | 0.010 |
Why?
| | Melanoma-Specific Antigens | 1 | 2002 | 3 | 0.010 |
Why?
| | Cell Communication | 1 | 2003 | 72 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 16 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2003 | 147 | 0.010 |
Why?
| | Cohort Studies | 1 | 2006 | 1541 | 0.010 |
Why?
| | Immunoglobulins | 1 | 2002 | 76 | 0.010 |
Why?
| | Database Management Systems | 1 | 2002 | 27 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2005 | 1214 | 0.010 |
Why?
| | Logistic Models | 1 | 2003 | 925 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 1518 | 0.010 |
Why?
|
|
Zhan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|